Department of Basic Sciences/Pathology, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.
Department of Surgery, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.
Cell Mol Biol (Noisy-le-grand). 2020 Aug 31;66(7):131-135.
Glioma is one of the primary tumors of the central nervous system that occurs in the spinal cord or brain and the origin of the tumor is from glial cell cells. The most common site of glioma tumors is the brain. Glioma accounts for 30% of all central nervous system tumors and 80% of malignant brain tumors. Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutations are frequently distinguished in gliomas. Current research is an attempt to assess ATRX immunoexpression in different types of gliomas diagnosed, in Erbil-Iraq, and to evaluate its association with patient's age, gender, tumor location, grade and type. From January 2015 to January 2017, we reviewed and analyzed 97 cases of glioma. Immunohistochemical staining, for ATRX, was performed using an automated immunostainer technique. According to the WHO grading system for brain tumors, 16 (16.5%) cases were grade I gliomas, 27 (27.8%) were grade II, 10 (10.3%) were anaplastic gliomas (grade III), and 44 (45.3%) cases were glioblastomas WHO (grade IV). Positive ATRX immunoexpression was demonstrated in 27 (27.8%) cases. The highest rates of ATRX expression (55.6%) were among 30-39 years' age group, supratentorial (34.2%), and among grade II and III tumors (40.7% and 30% respectively). A significant association was observed between ATRX expression and patient's age, tumor location, tumor type and grade (p-values 0.010, 0.004, 0.004, and 0.037 respectively). No significant association was found between ATRX expression and patient's gender (p-value 0.097). It was found that ATRX is frequently expressed in grade II and III astrocytomas and was significantly related to the patient's age, tumor location, type and grade, so it can be used as a good diagnostic and prognostic indicator for glioma.
神经胶质瘤是一种发生在脊髓或大脑中的中枢神经系统原发性肿瘤，其肿瘤起源于神经胶质细胞。神经胶质瘤最常见的部位是大脑。神经胶质瘤占所有中枢神经系统肿瘤的 30%，占恶性脑肿瘤的 80%。α-地中海贫血/智力迟钝综合征 X 连锁（ATRX）突变在神经胶质瘤中经常被发现。目前的研究试图评估在伊拉克埃尔比勒诊断的不同类型的神经胶质瘤中 ATRX 的免疫表达，并评估其与患者年龄、性别、肿瘤位置、分级和类型的关系。从 2015 年 1 月至 2017 年 1 月，我们回顾性分析了 97 例神经胶质瘤病例。使用自动化免疫染色技术对 ATRX 进行免疫组织化学染色。根据脑肿瘤世界卫生组织分级系统，16 例（16.5%）为 I 级神经胶质瘤，27 例（27.8%）为 II 级，10 例（10.3%）为间变性神经胶质瘤（III 级），44 例（45.3%）为胶质母细胞瘤（IV 级）。27 例（27.8%）显示 ATRX 免疫表达阳性。ATRX 表达率最高（55.6%）的是 30-39 岁年龄组、幕上（34.2%）和 II 级和 III 级肿瘤（分别为 40.7%和 30%）。ATRX 表达与患者年龄、肿瘤位置、肿瘤类型和分级之间存在显著相关性（p 值分别为 0.010、0.004、0.004 和 0.037）。ATRX 表达与患者性别之间无显著相关性（p 值为 0.097）。研究发现，ATRX 在 II 级和 III 级星形细胞瘤中常表达，与患者年龄、肿瘤位置、类型和分级显著相关，因此可作为神经胶质瘤的良好诊断和预后指标。
